Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Pamela L Zeitlin,1 Mila Leong,2 Jeremy Cole,3 Raburn M Mallory,4 Vivian H Shih,5 Richard F Olsson,6 Mitchell Goldman5 On behalf of the ALIZE study investigators 1Department of Pediatrics, National Jewish Health, Denver, CO, USA; 2Pediatric Pulmonary and Asthma Associates, Northfield, NJ, USA; 3OK Cl...

Full description

Bibliographic Details
Main Authors: Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M
Format: Article
Language:English
Published: Dove Medical Press 2018-08-01
Series:Journal of Asthma and Allergy
Subjects:
benralizumab
interleukin-5
interleukin-5 receptor
influenza vaccination
eosinophils
antibody response
asthma
Online Access:https://www.dovepress.com/benralizumab-does-not-impair-antibody-response-to-seasonal-influenza-v-peer-reviewed-article-JAA

Internet

https://www.dovepress.com/benralizumab-does-not-impair-antibody-response-to-seasonal-influenza-v-peer-reviewed-article-JAA

Similar Items